Opendata, web and dolomites

LIFT SIGNED

Liquid Foam Therapy (LIFT) for Acute Respiratory Distress Syndrome (ARDS)

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 LIFT project word cloud

Explore the words cloud of the LIFT project. It provides you a very rough idea of what is the project "LIFT" about.

microfabricated    endotracheal    reduces    doses    advocate    ards    clinical    surfactant    treat    aerosols    babies    device    fluoroscopy    optimize    coating    brings    patent    vivo    chest    annually    respiratory    carrier    therapeutic    leaving    expertise    anesthetized    abundance    neonates    fail    drowning    obstructive    3d    care    biomedical    span    models    copd    excised    treatment    100ml    saving    40    liquid    therapies    distress    lay    feasibility    life    acute    administration    drains    experiments    shift    homogeneously    srt    hurdles    syndrome    head    overcome    foam    business    poc    regions    age    small    bridges    gravity    pools    run    pig    medicine    extend    broadly    animal    meanwhile    demonstrated    airway    ex    patients    pending    inflammatory    team    hr    injury    fibrosis    therapy    133    intensive    inner    lift    lung    mortality    pneumonia    newborn    larger    rates    1ml    inadequate    expand    nebulizers    distributes    lungs    caused    idiopathic    tension    formulation    replacement    procedure    engineering    untreated    ipf    255    instillations    lt    pulmonary    leveraged    people    construct    paradigm    sepsis    depletion    disease    printed    vitro    forces    groups    surface    inhalation    cell    children    chronic    adults    stem   

Project "LIFT" data sheet

The following table provides information about the project.

Coordinator
TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY 

Organization address
address: SENATE BUILDING TECHNION CITY
city: HAIFA
postcode: 32000
website: www.technion.ac.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-PoC
 Funding Scheme ERC-POC
 Starting year 2018
 Duration (year-month-day) from 2018-10-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY IL (HAIFA) coordinator 150˙000.00

Map

 Project objective

Acute Respiratory Distress Syndrome (ARDS) is an inflammatory lung condition caused e.g. by sepsis, pneumonia and head or chest injury, affecting annually 133,000 people in Europe and 255,000 in the US. ARDS is characterized by the depletion of the lungs’ inner liquid coating (pulmonary surfactant), which reduces surface tension forces and allows the lungs to expand. Patients span across all age groups and lay anesthetized in the intensive care unit with mortality rates at 40%. Although surfactant replacement therapy (SRT) is a life-saving procedure in newborn neonates, current administration methods to treat adults and even children remain inadequate. Endotracheal surfactant liquid instillations used in babies fail in larger lungs: liquid drains into pools, drowning these lung regions while leaving others untreated. Meanwhile, inhalation aerosols can only deliver small doses (<1ml/hr for nebulizers), far from the required ~100ml of surfactant. To overcome such hurdles, we advocate using liquid foam as a surfactant carrier to the lungs, i.e. LIquid Foam Therapy (LIFT). Foam is weakly affected by gravity, distributes homogeneously within lungs and in abundance. LIFT brings a paradigm shift in SRT, and more broadly, in the field of therapeutic pulmonary delivery. Our team bridges expertise in clinical ARDS treatment in neonates, pulmonary medicine, biomedical engineering and business. Together, we have demonstrated the feasibility of our patent pending technology, both in vitro in 3D printed and microfabricated airway models, and ex vivo in excised pig lungs using fluoroscopy. In this PoC, we will optimize the foam formulation, design and construct a delivery device, and run pre-clinical in vivo animal experiments. LIFT has the potential to extend far beyond ARDS treatment and be leveraged for other lung therapies, such as stem cell delivery directly to the lungs to treat Idiopathic Pulmonary Fibrosis (IPF) and Chronic Obstructive Pulmonary Disease (COPD).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LIFT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LIFT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

IMMUNOTHROMBOSIS (2019)

Cross-talk between platelets and immunity - implications for host homeostasis and defense

Read More  

RODRESET (2019)

Development of novel optogenetic approaches for improving vision in macular degeneration

Read More